High blood pressure represents one of the leading risk factors for the development of stroke and its recurrence. This explains why blood pressure control is a major objective of antihypertensive treatment, both in primary and secondary prevention of this cerebrovascular disease. This paper reviews the evidence provided by randomized clinical trials on the favorable effects exerted by blood pressure reduction on this end point. Emphasis is given to the results of recently published clinical trials documenting that drugs acting on the renin-angiotensin system may exert cerebrovascular protective effects additive to the ones associated with blood pressure reduction.
Grassi, G., Arenare, F., QUARTI TREVANO, F., Dell'Oro, R., Mancia, G. (2007). Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. CURRENT HYPERTENSION REPORTS, 9(4), 299-304 [10.1007/s11906-007-0055-x].
Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials
GRASSI, GUIDO;QUARTI TREVANO, FOSCA ANNA LUISA;DELL'ORO, RAFFAELLA;MANCIA, GIUSEPPE
2007
Abstract
High blood pressure represents one of the leading risk factors for the development of stroke and its recurrence. This explains why blood pressure control is a major objective of antihypertensive treatment, both in primary and secondary prevention of this cerebrovascular disease. This paper reviews the evidence provided by randomized clinical trials on the favorable effects exerted by blood pressure reduction on this end point. Emphasis is given to the results of recently published clinical trials documenting that drugs acting on the renin-angiotensin system may exert cerebrovascular protective effects additive to the ones associated with blood pressure reduction.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
